Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001 Oct 10;213(1):4-13
Date
12/19/2001Pubmed ID
11747351DOI
10.1006/cimm.2001.1864Scopus ID
2-s2.0-0035841263 (requires institutional sign-in at Scopus site) 54 CitationsAbstract
The absence of surface costimulatory molecules explains in part the lack of an effective anti-tumor immune response in tumor-bearing animals, even though unique tumor antigens may be presented by class I MHC. We determined that the immunogenicity of a murine neuroblastoma, Neuro-2a, which lacks surface costimulatory molecules, could be increased by electrically induced fusion with dendritic cells. Electrofusion induced a higher level of cell fusion than polyethylene glycol, and tumor/dendritic cell heterokaryons expressed high levels of costimulatory molecules. While Neuro-2a was unable to induce the proliferation of syngeneic or allogeneic T cells in vitro, fused cells were able to induce T cell responses both in vitro and in vivo. When fused dendritic tumor cells were used as a cancer vaccine, immunized mice were significantly protected from challenge with Neuro-2a. We propose that electrofusion with patient-derived tumor and dendritic cells may provide a rapid means to produce patient-specific tumor vaccines.
Author List
Orentas RJ, Schauer D, Bin Q, Johnson BDAuthor
Bryon D. Johnson PhD Adjunct Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAntigens, CD
B7-1 Antigen
B7-2 Antigen
Bone Marrow Cells
Cancer Vaccines
Cell Fusion
Dendritic Cells
H-2 Antigens
Histocompatibility Antigens Class II
Hybrid Cells
Intercellular Adhesion Molecule-1
Membrane Glycoproteins
Mice
Mice, Inbred A
Mice, Inbred C57BL
Neoplasm Transplantation
Neoplasms, Experimental
Neuroblastoma
Survival Rate
T-Lymphocytes
Tumor Cells, Cultured
Vaccination
